Strategies for effective neutralizing cell-based assays in early immunogenicity risk assessment

Written by Paul Rhyne, PhD Scientific Director, Bioanalytical and ADME Immunoassay Services, Q2 Solutions

This white paper reviews antibody-based immune responses, and discusses the role of neutralizing antibody assays, challenges in their design, and the need for a clear immunogenicity strategy to assess and mitigate risk during drug development.

Click here for to read the full article.